TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02800564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active mass media approach
Description: Communities will be exposed to twice weekly radio programming for up to 18 months. Interactive voice response systems (IVRS) will be promoted where listeners can chose to receive pre-recorded audio/voice messages or text messages on mobile phones. Messages will be consistent with the weekly radio program. The topic of the radio program will be discussed in monthly open community meetings. Each individual may choose to participate or not to listen to the radio program, receive the IVRS system, and attend monthly meetings.
Study: NCT04227587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zero Time Exercise
Description: Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
Study: NCT02261896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Evaluate usefullness of antibiotic prophylaxis
Study: NCT02800564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive mass media approach
Description: These communities will be exposed to twice weekly radio programming for up to 18 months only.
Study: NCT04227587

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene education
Description: We offer a 2-session education course to teach the subjects about sleep hygiene practice.
Study: NCT01714674

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary nitrate beverage
Description: ingestion of single dose NaNO3 beverage two hours prior to exercise bout

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NaCl beverage
Description: ingestion of single dose NaCl beverage two hours prior to exercise bout
Study: NCT02261896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Ciprofloxacine 400 mg intravenous one dose followed by ciprofloxacine oral each 12 hours (complete 3 days)
Study: NCT01823055

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal suture capturing mesh device
Description: The Uphold™ LITE vaginal support system is an intra-vaginal approach to apical and anterior vaginal wall prolapse repair that utilizes a suture capturing device to place the mesh. After primary dissection the suturing device is used to pull the mesh through the sacrospinous ligament, medial to the ischial spine. An anterior colporraphy was allowed following the Uphold™ LITE procedure at the discretion of the surgeon if deemed necessary.
Study: NCT00137592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: small media, group education (multicomponent)
Study: NCT00621283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1068 (Synthetic Human Secretin)
Description: Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
Study: NCT01029002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D, ergocalciferol, 50000 IU, weekly for 12 weeks, with open label extension for another 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to this arm will receive one placebo pill once weekly.
Study: NCT00775658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olopatadine
Description: olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olopatadine
Description: olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day
Study: NCT01931462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave pre-coagulation
Description: The Certus 140™ system is used for microwave pre-coagulation of the tissue around the part of the kidney to be removed. This is done in place of the standard clamping to stop blood loss.
Study: NCT00837512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle
Description: Microneedle used to deliver insulin at a depth less than 900 micrometers
Study: NCT00775658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day
Study: NCT01352962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1,000mg/m2 IVPB over 30 min x 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1,000mg/m2 IVPB over 30 min x 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5\*\* IVPB over 30 min x 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5\*\* IVPB over 30 min x 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Escalating Doses starting at 2.5 po daily up to 25 mg po daily until MTD is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Escalating Doses starting at 2.5 po daily up to 25 mg po daily until MTD is reached.
Study: NCT03687528

Intervention type: RADIATION
Intervention: CT-scanner
Description: After a clinical exam, patient have a CT-scanner to check any cerebral haemorrhage.
Study: NCT04128566

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: walking stress test
Description: walk for 30 minutes on a treadmill with either one of the three loading conditions (reduced load = 80% Bodyweight (BW), normal load = 100% BW, increased load = 120% BW). The order of experimental condition will be applied in randomized order determined by block randomization, and the same self-selected walking speed will be used for all conditions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: walking stress test
Description: walk for 30 minutes on a treadmill with either one of the three loading conditions (reduced load = 80% Bodyweight (BW), normal load = 100% BW, increased load = 120% BW). The order of experimental condition will be applied in randomized order determined by block randomization, and the same self-selected walking speed will be used for all conditions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: walking stress test
Description: walk for 30 minutes on a treadmill with either one of the three loading conditions (reduced load = 80% Bodyweight (BW), normal load = 100% BW, increased load = 120% BW). The order of experimental condition will be applied in randomized order determined by block randomization, and the same self-selected walking speed will be used for all conditions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: walking stress test
Description: walk for 30 minutes on a treadmill with either one of the three loading conditions (reduced load = 80% Bodyweight (BW), normal load = 100% BW, increased load = 120% BW). The order of experimental condition will be applied in randomized order determined by block randomization, and the same self-selected walking speed will be used for all conditions.
Study: NCT03650764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient
Study: NCT00837512

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous insulin catheter
Description: Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
Study: NCT00369668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bilateral movements and neuromuscular electrical stimulation
Description: Participants practice moving their paretic arm at the same time as they move their non-paretic arm in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 4 times per week for 2 weeks.
Study: NCT03650764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is commercially available

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is commercially available

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-30
Description: -Screening, start of cycle 2, start of cycle 5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACT H&N
Description: -Screening, start of cycle 2, start of cycle 5

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood
Description: -Baseline

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood
Description: -Baseline
Study: NCT04422899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV007
Description: intravitreal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV007
Description: intravitreal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV007
Description: intravitreal
Study: NCT01160185

Intervention type: DRUG
Intervention: paclitaxel
Description: paclitacel

Intervention type: DRUG
Intervention: cisplatin
Description: cisplatin monotherapy
Study: NCT00369668

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral movements and neuromuscular electrical stimulation
Description: Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 2 times per week for 2 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral movements and sham electrical stimulation
Description: Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Sham electrical stimulation (low level electrical stimulation that can be felt but is insufficient to trigger a muscle contraction) is provided to the paretic arm during the movement. Training period was 2 times per week for 2 weeks.
Study: NCT03415919

Intervention type: OTHER
Intervention: no intervention will be given to patients.
Description: samples are collected at the time of a scheduled procedure that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.

Intervention type: OTHER
Intervention: no intervention will be given to patients.
Description: samples are collected at the time of a scheduled procedure that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
Study: NCT01160185

Intervention type: DRUG
Intervention: cisplatin
Description: cisplatin monotherapy

Intervention type: DRUG
Intervention: cisplatin
Description: cisplatin monotherapy

Intervention type: DRUG
Intervention: topotecan
Description: topotecan
Study: NCT02502552

Intervention type: OTHER
Intervention: blood specimen
Description: blood specimen
Study: NCT02075060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPOI (pre-operative)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPOP (post-operative)
Study: NCT03616340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shoulder injection
Description: intra articular or subacromial shoulder injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shoulder injection
Description: intra articular or subacromial shoulder injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: knee injection
Description: intra-articular knee injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: knee injection
Description: intra-articular knee injection
Study: NCT01342055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apetrol ES
Description: sequences of administered drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apetrol ES
Description: sequences of administered drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apetrol ES
Description: sequences of administered drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apetrol ES
Description: sequences of administered drugs
Study: NCT03436446

Intervention type: OTHER
Intervention: Interview
Description: Interviews will be conducted with orthopedic patients to review the construction and phrasing of various social incentives aimed at promoting patient reported outcome collection amongst post-operative patients.
Study: NCT03430687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Given intravesically
Study: NCT03212404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-301 (cosibelimab)
Description: CK-301 will be administered in periods of 28-day cycles.
Study: NCT02335216

Intervention type: DEVICE
Intervention: Implantation with the commercially available Axium neurostimulator
Study: NCT01487668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Goals Collaborative Care
Description: LGCC consists of 1) 10 self-management sessions that cover personal goal-setting and mental health symptom management reinforced through healthy lifestyles; 2) medical care management that includes identification of patient medical risk factors, monitoring of patient symptoms and medical needs via a registry over time; and 3) support for provider guidelines and community linkages.
Study: NCT03649100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: Conventional implant placement. Implant site development was prepared according to the manufacturer's instruction by the investigator, before knowing the randomized implant (NH or SA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: Conventional implant placement. Implant site development was prepared according to the manufacturer's instruction by the investigator, before knowing the randomized implant (NH or SA).
Study: NCT02083510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Study: NCT01401010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doripenem
Description: 500 mg every 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doripenem
Description: 1000 mg every 8 hours
Study: NCT04604106

Intervention type: DIAGNOSTIC_TEST
Intervention: Eyetracker
Description: Eye-tracking is an objective, non-invasive method and particularly suited to assess neurodevelopmental outcome in infants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Eyetracker
Description: Eye-tracking is an objective, non-invasive method and particularly suited to assess neurodevelopmental outcome in infants.
Study: NCT01342055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apetrol ES
Description: sequences of administered drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apetrol ES
Description: sequences of administered drugs
Study: NCT04604106

Intervention type: DIAGNOSTIC_TEST
Intervention: Ages & Stages questionnaire
Description: The Ages \& Stages Questionnaire is a conventional instrument used to measure developmental outcome in infants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ages & Stages questionnaire
Description: The Ages \& Stages Questionnaire is a conventional instrument used to measure developmental outcome in infants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bayley Scale of Infant Development
Description: The Bayley Scale of Infant Development is a conventional instrument used to measure developmental outcome in infants.
Study: NCT03289403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunomodulatory
Description: Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Moreover, patients will receive a treatment course of immunomodulatory drugs for 3 -6 months before ICSI cycle:~1. Prednisnlone 40mg for 2 weeks to be lowered gradually till become 5mg after 6 weeks and to be continued~2. Hydroxychloroquine according to body weight, patients who develop hypersensitivity will be shifted to Azathioprin.~3. Immunoglobulins will be used in cases not responding to treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thyroxine
Description: Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Patients will not receive immunomodulatory drugs
Study: NCT03375242

Intervention type: DRUG
Intervention: crizotinib
Description: XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status.
Study: NCT03148002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current Bowel Protocol (senna/lactulose)
Description: Stimulant and Osmotic Laxatives.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG Bowel Protocol (PEG/lactulose)
Description: Osmotic Laxatives.
Study: NCT03828604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress; Trier Social Stress Task
Description: Standardized acute psychosocial stressor

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Trier Social Stress Task
Description: Active control version of the TSST
Study: NCT04489797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Participants will receive single oral dose of acalabrutinib on day 1 as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Participants will receive single oral dose of acalabrutinib on day 1 as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Participants will receive twice daily oral dose of 20 mg rabeprazole on days -3, -2, and -1.
Study: NCT01315665

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccoli sprouts
Description: Subjects (both healthy volunteers and subjects with cystic fibrosis) will consume 100 gm of raw broccoli sprouts once daily for 5 consecutive days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccoli sprouts
Description: Subjects (both healthy volunteers and subjects with cystic fibrosis) will consume 100 gm of raw broccoli sprouts once daily for 5 consecutive days.
Study: NCT01431989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL
Description: Test formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxil® 500mg/5mL powder for oral suspension
Description: Reference formulation
Study: NCT00091442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL
Description: DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
Study: NCT03847246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baraclude® tablets,1.0 mg
Description: oral,once,under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir tablets,1.0 mg
Description: oral,once,under fasting condition
Study: NCT00581243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-313 SR
Description: sustained relase tablets taken once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-313 SR
Description: sustained relase tablets taken once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-313 SR
Description: sustained relase tablets taken once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-313 SR
Description: sustained relase tablets taken once daily for 14 days
Study: NCT03605589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT03417219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and Skill Building Rehabilitation-mobile (ESBR-m)
Description: Participants randomized to the ESBR-m group will participate in four, 90-minute group ( 5 participants) sessions. These four sessions are supplemented with a booster session one month following the last intervention session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: Participants randomized to the UC group will receive supplemental educational materials (e.g., VA Caregiver Support Program; Veterans Crisis Line; National Institute on Aging's Understanding Memory Loss).
Study: NCT02699814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: H3 Services
Description: A community-based integrated care model to improve the prevention, early detection and treatment of child mental health problems
Study: NCT03345914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: Solution for injection in pre-filled syringe;~Route of administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: Solution for injection in pre-filled syringe;~Route of administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Pharmaceutical form: Solution for injection;~Route of administration: Subcutaneous (SC)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Treatment: Topical Corticosteroids
Description: All participants are required to initiate treatment with a medium potency TCS using a standardized regimen. It is recommended that participants use triamcinolone acetonide 0.1% cream, fluocinolone acetonide 0.025% cream, or clobetasone butyrate 0.05%.